ABSTRACT
Current estimates indicate that about 90% of drugs in development
pipelines exhibit a combination of poor water solubility and
poor permeability.1 About 70% of these exhibit good perme-
ability but are solubility limited. These drugs, known by the
Biopharmaceutical Classification System as class 2 compounds,
are amenable to bioavailability enhancement through solubility
enhancement pathways. By simply increasing drug concentration in
the gastrointestinal tract (GIT), in vivo absorption can be enhanced.
Hence, the application of solubility enhancement platforms to drugs
in development has become increasingly common.
